Alcon joins forces with pharma giant

Article

Alcon is continuing to invest heavily in its future drug portfolio by forging links with GlaxoSmithKline (GSK) for the global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor, and by expanding an existing alliance with Origenis GmbH for the discovery and development of small molecules.

Alcon is continuing to invest heavily in its future drug portfolio by forging links with GlaxoSmithKline (GSK) for the global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor, and by expanding an existing alliance with Origenis GmbH for the discovery and development of small molecules.

Alcon believes that GSK's cilomilast may have applications against numerous ophthalmic conditions, including dry eye. Alcon will provide GSK with an initial, upfront payment and future payments on the achievement of predefined milestones.

The company has also expanded its current research agreement with Origenis GmbH focused on the discovery and development of small molecule therapeutics for ophthalmic conditions. Alcon will provide Origenis with payments for milestone achievements and sales royalties; Alcon will retain the rights to any drug candidates with ophthalmic indications that are discovered during the collaboration.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.